Selection and Qualification of Simplified QSP Models When Using Model Order Reduction Techniques
暂无分享,去创建一个
[1] L. Aarons,et al. Proper lumping in systems biology models. , 2009, IET systems biology.
[2] Masoud Jamei,et al. Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance , 2016, Current Pharmacology Reports.
[3] A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling , 2015, Journal of Pharmacokinetics and Pharmacodynamics.
[4] V. Chernick,et al. Remodeling , 2006 .
[5] Matthew M Riggs,et al. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.
[6] O Demin,et al. Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors , 2013, CPT: pharmacometrics & systems pharmacology.
[7] B Ribba,et al. Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation , 2017, CPT: pharmacometrics & systems pharmacology.
[8] P Chan,et al. Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance , 2013, CPT: pharmacometrics & systems pharmacology.
[9] Leon Aarons,et al. Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data , 2015, The AAPS Journal.
[10] Leon Aarons,et al. Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics , 2015, Journal of Pharmacokinetics and Pharmacodynamics.
[11] M. Rashid,et al. A mechanistic model for internal bone remodeling exhibits different dynamic responses in disuse and overload. , 2001, Journal of biomechanics.
[12] Leon Aarons,et al. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.
[13] William L. Goffe,et al. SIMANN: FORTRAN module to perform Global Optimization of Statistical Functions with Simulated Annealing , 1992 .
[14] S B Duffull,et al. Scale Reduction of a Systems Coagulation Model With an Application to Modeling Pharmacokinetic–Pharmacodynamic Data , 2014, CPT: pharmacometrics & systems pharmacology.
[15] V Shivva,et al. An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models , 2013, CPT: pharmacometrics & systems pharmacology.
[16] Thomas J. Snowden,et al. A combined model reduction algorithm for controlled biochemical systems , 2017, BMC Systems Biology.
[17] R. Eastell,et al. Cancellous bone remodeling in type i (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] Neil Benson,et al. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.
[19] Chihiro Hasegawa,et al. Exploring inductive linearization for pharmacokinetic–pharmacodynamic systems of nonlinear ordinary differential equations , 2018, Journal of Pharmacokinetics and Pharmacodynamics.
[20] Neil Benson,et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology , 2013, Interface Focus.
[21] Thomas J. Snowden,et al. Methods of Model Reduction for Large-Scale Biological Systems: A Survey of Current Methods and Trends , 2017, Bulletin of Mathematical Biology.
[22] T. Wajima,et al. A Comprehensive Model for the Humoral Coagulation Network in Humans , 2009, Clinical pharmacology and therapeutics.
[23] MC Peterson,et al. FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.
[24] Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data , 2015, Journal of Pharmacokinetics and Pharmacodynamics.
[25] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[26] P. Pickkers,et al. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers , 2016, Clinical Pharmacokinetics.
[27] Janet R. Wade,et al. A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective , 2005, The AAPS Journal.
[28] Wilhelm Huisinga,et al. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models , 2010, Journal of Pharmacokinetics and Pharmacodynamics.